Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SDAI ( (SG:5TI) ) has issued an update.
SDAI Limited’s wholly owned unit SDAI Healthcare has signed a cooperation agreement with Singapore-based LiveBeyond to support the commercialisation of longevity-related products, including alpha-ketoglutarate offerings. LiveBeyond, which specialises in longevity research and provides access to experts such as Dr Brian Kennedy and Dr Chong He, will deliver technology sourcing, scientific validation, strategic market support and exclusive scientific endorsement for AKG products in agreed territories.
The fee structure will be tied to a percentage of SDAI Healthcare’s net revenue from these products, subject to a minimum, with a phased ramp-up aligned to expected commercial scale-up. The deal marks a concrete step in SDAI’s recently approved move into biotechnology, though management cautions that there is no certainty the related supplier agreement will be executed or that commercial objectives will be fully realised, and notes that the cooperation is not expected to materially affect 2026 earnings at this stage.
More about SDAI
SDAI Limited, incorporated in Singapore, operates through its subsidiary SDAI Healthcare Pte. Ltd. in the biotechnology sector, focusing on longevity and anti-ageing products such as alpha-ketoglutarate-based supplements. The group is diversifying from its previous core businesses into healthcare and biotech, targeting markets including China and Singapore as it builds capabilities in scientific validation and commercialisation of novel longevity solutions.
Current Market Cap: S$33.97M
For an in-depth examination of 5TI stock, go to TipRanks’ Overview page.